COVID-19 Vaccine Development

• Biopharmaceutical Development on COVID:19

COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments.  The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa

The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness